DE69026615D1 - Igg3-antikörper mit verkürzter hinge-region und einem komplementaktivierungstest - Google Patents

Igg3-antikörper mit verkürzter hinge-region und einem komplementaktivierungstest

Info

Publication number
DE69026615D1
DE69026615D1 DE69026615T DE69026615T DE69026615D1 DE 69026615 D1 DE69026615 D1 DE 69026615D1 DE 69026615 T DE69026615 T DE 69026615T DE 69026615 T DE69026615 T DE 69026615T DE 69026615 D1 DE69026615 D1 DE 69026615D1
Authority
DE
Germany
Prior art keywords
pct
complement activation
antibody
hinge region
complement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69026615T
Other languages
English (en)
Other versions
DE69026615T2 (de
Inventor
Terje Michaelsen
Inger Sandlie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
STATENS INSTITUTT FOR FOLKEHELSE, OSLO, NO
Original Assignee
Dynal AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynal AS filed Critical Dynal AS
Application granted granted Critical
Publication of DE69026615D1 publication Critical patent/DE69026615D1/de
Publication of DE69026615T2 publication Critical patent/DE69026615T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
DE69026615T 1989-07-18 1990-07-17 Igg3-antikörper mit verkürzter hinge-region und einem komplementaktivierungstest Expired - Fee Related DE69026615T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898916400A GB8916400D0 (en) 1989-07-18 1989-07-18 Modified igg3
PCT/EP1990/001172 WO1991001335A1 (en) 1989-07-18 1990-07-17 IgG3 ANTIBODIES WITH SHORTENED HINGE REGION AND A COMPLEMENT ACTIVATION TEST

Publications (2)

Publication Number Publication Date
DE69026615D1 true DE69026615D1 (de) 1996-05-23
DE69026615T2 DE69026615T2 (de) 1996-09-26

Family

ID=10660201

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69026615T Expired - Fee Related DE69026615T2 (de) 1989-07-18 1990-07-17 Igg3-antikörper mit verkürzter hinge-region und einem komplementaktivierungstest

Country Status (8)

Country Link
US (1) US5348876A (de)
EP (1) EP0483194B1 (de)
JP (1) JPH05500303A (de)
AT (1) ATE136909T1 (de)
DE (1) DE69026615T2 (de)
DK (1) DK0483194T3 (de)
GB (1) GB8916400D0 (de)
WO (1) WO1991001335A1 (de)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7033589B1 (en) 1997-02-20 2006-04-25 Biogen Idec Ma Inc. γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US6893636B2 (en) * 1997-02-20 2005-05-17 Biogen Idec Ma Inc. Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
EP1746107B1 (de) 1998-04-02 2014-12-17 Genentech, Inc. Antikörpervarianten und deren Fragmente
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2000042072A2 (en) * 1999-01-15 2000-07-20 Genentech, Inc. Polypeptide variants with altered effector function
US6193892B1 (en) 1999-03-03 2001-02-27 Promega Corporation Magnetic separation assembly and method
AU5345901A (en) * 2000-04-13 2001-10-30 Univ Rockefeller Enhancement of antibody-mediated immune responses
FR2836146B1 (fr) * 2002-02-15 2005-01-07 Urrma R & D IMMUNOGLOBULINE IgG3 MARQUEUR DE PROTECTION CONTRE LES MALADIES VIRALES INFECTIEUSES ET SES UTILISATIONS
US8530627B2 (en) * 2002-08-14 2013-09-10 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8187593B2 (en) * 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8044180B2 (en) * 2002-08-14 2011-10-25 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8946387B2 (en) * 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8193318B2 (en) * 2002-08-14 2012-06-05 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
JP4033390B2 (ja) * 2002-10-30 2008-01-16 独立行政法人科学技術振興機構 不死化ナチュラルキラー細胞株
EP1578447A4 (de) * 2002-10-31 2009-06-03 Genentech Inc Verfahren und zusammensetzungen zur erhöhung der antikörper-produktion
US7960512B2 (en) * 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP2368578A1 (de) 2003-01-09 2011-09-28 Macrogenics, Inc. Identifizierung und Herstellung von Antikörpern mit abweichenden FC-Regionen und Anwendungsverfahren dafür
WO2005000899A2 (en) * 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
WO2005027966A2 (en) * 2003-09-05 2005-03-31 Genentech, Inc. Antibodies with altered effector functions
WO2005063820A2 (en) * 2003-12-30 2005-07-14 Merck Patent Gmbh Il-7 fusion proteins
US8309318B2 (en) * 2004-02-10 2012-11-13 Brendan Bioscience, Llc Detection of antigen specific immunocomplexes
WO2005078442A1 (en) * 2004-02-10 2005-08-25 Dantini Daniel C Comprehensive food allergy test
WO2005110474A2 (en) * 2004-05-10 2005-11-24 Macrogenics, Inc. HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
EP2213683B1 (de) 2004-08-04 2013-06-05 Mentrik Biotech, LLC Varianten der Fc Regionen
AU2005285347A1 (en) * 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
EP1789446A2 (de) * 2004-09-02 2007-05-30 Genentech, Inc. Heteromultimere moleküle
US7632497B2 (en) * 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
EP1674479A1 (de) * 2004-12-22 2006-06-28 Memorial Sloan-Kettering Cancer Center Modulierung von Fc-gamma-Rezeptoren zur Optimierung einer Immunotherapie
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
ES2592271T3 (es) 2005-03-31 2016-11-29 Chugai Seiyaku Kabushiki Kaisha Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos
US9963510B2 (en) * 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US9284375B2 (en) * 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US9296816B2 (en) * 2005-04-15 2016-03-29 Macrogenics, Inc. Covalent diabodies and uses thereof
US11254748B2 (en) 2005-04-15 2022-02-22 Macrogenics, Inc. Covalent diabodies and uses thereof
WO2006116260A2 (en) 2005-04-26 2006-11-02 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
DK1919503T3 (en) * 2005-08-10 2014-12-15 Macrogenics Inc Identification and preparation of antibodies with variant fc regions and methods of use thereof
CA2644903A1 (en) * 2006-03-10 2007-09-20 Macrogenics, Inc. Identification and engineering of antibodies with variant heavy chains and methods of using same
GB2436616A (en) * 2006-03-29 2007-10-03 Inverness Medical Switzerland Assay device and method
EP4001409A1 (de) 2006-03-31 2022-05-25 Chugai Seiyaku Kabushiki Kaisha Verfahren zur kontrolle der blutkinetik eines antikörpers
WO2007114325A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 二重特異性抗体を精製するための抗体改変方法
ES2489646T3 (es) 2006-05-26 2014-09-02 Macrogenics, Inc. Anticuerpos humanizados específicos a Fc gamma RIIB y sus métodos de uso
EP2032159B1 (de) * 2006-06-26 2015-01-07 MacroGenics, Inc. Kombination aus fcgammariib-antikörpern und cd20-spezifischen antikörpern sowie verwendungsverfahren dafür
EP2505209A1 (de) 2006-06-26 2012-10-03 MacroGenics, Inc. Fcgamma-RIIB-spezifische Antikörper und Verfahren zu ihrer Anwendung
WO2008007159A1 (en) * 2006-07-14 2008-01-17 Eötvös Lorand University Measurement of complement activation products on antigen arrays
US20080112961A1 (en) * 2006-10-09 2008-05-15 Macrogenics, Inc. Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
US8652466B2 (en) * 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
MX342551B (es) 2007-09-26 2016-10-04 Chugai Pharmaceutical Co Ltd Region constante de anticuerpo modificada.
WO2009117030A2 (en) * 2007-12-19 2009-09-24 Macrogenics, Inc. Improved compositions for the prevention and treatment of smallpox
MX2010010387A (es) 2008-04-02 2010-10-15 Macrogenics Inc Anticuerpos especificos para el complejo de bcr y metodos para el uso de los mismos.
DK2247304T3 (en) 2008-04-02 2016-09-26 Macrogenics Inc Her2 / neu-specific antibodies and methods of use thereof
US20110081347A1 (en) * 2008-06-04 2011-04-07 Macrogenics, Inc. Antibodies with Altered Binding to FcRn and Methods of Using Same
JP5787446B2 (ja) 2009-03-19 2015-09-30 中外製薬株式会社 抗体定常領域改変体
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
EP2481752B1 (de) * 2009-09-24 2016-11-09 Chugai Seiyaku Kabushiki Kaisha Modifizierte konstante antikörperregionen
EP2486141B1 (de) 2009-10-07 2018-01-10 MacroGenics, Inc. Fc-regionshaltige polypeptide mit besserer effektorfunktion aufgrund von änderungen des ausmasses einer fukosylierung sowie verwendungsverfahren dafür
NZ705128A (en) 2010-03-04 2015-04-24 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
WO2011108714A1 (ja) 2010-03-04 2011-09-09 中外製薬株式会社 抗体定常領域改変体
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
EP2601216B1 (de) 2010-08-02 2018-01-03 MacroGenics, Inc. Kovalente diabodies und deren verwendung
MX354359B (es) 2011-03-29 2018-02-28 Roche Glycart Ag Variantes de fragmento cristalizable (fc) de los anticuerpos.
AU2012259162C1 (en) 2011-05-21 2020-05-21 Macrogenics, Inc. Deimmunized serum-binding domains and their use for extending serum half-life
WO2014009465A1 (en) 2012-07-13 2014-01-16 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
AP2015008740A0 (en) 2013-03-14 2015-09-30 Macrogenics Inc Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
EP2840091A1 (de) 2013-08-23 2015-02-25 MacroGenics, Inc. Bispezifische Diabodies, die gpA33 und CD3 binden können und Anwendungen dieser
EP2839842A1 (de) 2013-08-23 2015-02-25 MacroGenics, Inc. Bispezifische monovalente Diabodies mit Fähigkeit zur Bindung von CD123 und CD3 und Verwendungen davon
SG11201602261VA (en) 2013-09-27 2016-04-28 Chugai Pharmaceutical Co Ltd Method for producing polypeptide heteromultimer
BR112017006515A8 (pt) 2014-09-29 2018-02-27 Univ Duke moléculas biespecíficas, composições, método para tratar ou prevenir infecção por hiv-1 em um indivíduo com essa necessidade, e vetor
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
CA3004288A1 (en) 2015-12-28 2017-07-06 Nobuyuki Tanaka Method for promoting efficiency of purification of fc region-containing polypeptide
CA3020864A1 (en) 2016-04-15 2017-10-19 Macrogenics, Inc. Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2840847A1 (de) * 1978-09-20 1980-04-03 Behringwerke Ag Verfahren zum nachweis und zur bestimmung komplementbindender antikoerper
AU600575B2 (en) * 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
FR2609398A1 (fr) * 1988-04-19 1988-07-15 Zagyansky Yuly Structure de l'igg plus antigene et complement, ses mecanismes et les consequences importantes
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
JP3095168B2 (ja) * 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体

Also Published As

Publication number Publication date
JPH05500303A (ja) 1993-01-28
DE69026615T2 (de) 1996-09-26
GB8916400D0 (en) 1989-09-06
WO1991001335A1 (en) 1991-02-07
US5348876A (en) 1994-09-20
DK0483194T3 (da) 1996-05-13
ATE136909T1 (de) 1996-05-15
EP0483194A1 (de) 1992-05-06
EP0483194B1 (de) 1996-04-17

Similar Documents

Publication Publication Date Title
DE69026615D1 (de) Igg3-antikörper mit verkürzter hinge-region und einem komplementaktivierungstest
ES2009939A6 (es) Un inmunoensayo para la deteccion simultanea de antigenos yno anticuerpos en una muestra a ensayar de un fluido fisiologico.
ES512498A0 (es) "metodo y su correspondiente aparato para el ensayo de anticuerpos con respecto a antigenos solubles".
DE3779704D1 (de) Verfahren und testkit zur bestimmung freier wirkstoffe in biologischen fluessigkeiten.
DE69106002T2 (de) Testverfahren und reagenziensatz dafür.
DE69124511T2 (de) Verfahren für den nachweis und/oder die bestimmung von hormonen
DE59509344D1 (de) Antikörperklassenspezifisches entstörungsreagenz
BR9507389A (pt) Método para detectar a presença de uma espécie mycobacterium e um kit e anticorpos para uso no mesmo
KR930008462A (ko) 치주질환과 관련된 미생물의 검증방법에서 높은 pH에서의 추출로 단백질을 보호하는 용도 및 이에 유용한 키트
DE3686717T2 (de) Immuntestverfahren.
Reid et al. Biological and chemical differences among proteins having reaginic activity
ATE188551T1 (de) Feststellung von antikörperproduktion
ATA261687A (de) Laktoferrin enthaltendes inkubationsmedium für festphasen-immunometrische verfahren und seine verwendung
DK608789A (da) Cea-immunanalyse uden falske positive foraarsaget af humant anti-museantistof
ATE286596T1 (de) Chemische modifikation von antikörpern und antigenen
ITMI930477A1 (it) Saggio per la determinazione di un antigene/anticorpo in un campione di prova e corredo per l'attuazione del saggio
DE3863270D1 (de) Immuntest.
ES8608321A1 (es) Hibridomas productores de anticuerpos monoclonales especifi-cos para la inmunoglobulina e (ige)humana del mieloma ns

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: STATENS INSTITUTT FOR FOLKEHELSE, OSLO, NO

8339 Ceased/non-payment of the annual fee